Australia has reached a pivotal turning point in the management of chronic weight issues, formally endorsing the use of GLP-1 medications—including semaglutide, commonly known by brand names like Ozempic and Wegovy—to treat obesity in patients at risk of cardiovascular disease (CVD). This shift, codified in the nation’s first Clinical Consensus Statement on Obesity and Cardiovascular Disease, marks a departure from treating weight loss as a matter of individual willpower and instead frames it as a critical component of heart health.
The guidelines, launched at the World Heart Summit in Geneva, Switzerland, establish a structured medical pathway for clinicians to treat the “interconnectedness” of obesity and heart disease. By integrating these medications into a formal care strategy, health practitioners now have a validated framework to reduce the risk of major cardiac events in a population where obesity rates have climbed steadily over the last two decades.
For patients like Tammy Merton, the endorsement is more than a clinical update; This proves a validation of a lifelong struggle. Merton, who has navigated the cycle of weight gain and loss for much of her adult life, previously found herself shamed by medical professionals when seeking help. After surviving a sudden cardiac arrest that resulted in a hypoxic brain injury and the implantation of a defibrillator, Merton experienced “cardiac blues,” finding it nearly impossible to maintain weight loss through traditional means.
“This is a huge step forward,” Merton said, noting that her lived experience helped inform the new consensus statement. “We’ll find that more people suffering from more than one issue are going to get far better help now.”
A Structured Pathway: The Four Pillars of Care
The new clinical consensus does not position medication as a first-line “quick fix.” Instead, it outlines a tiered approach to management, ensuring that pharmacological intervention is part of a holistic strategy. Professor Garry Jennings, co-chair of the task force and chief medical advisor for the Heart Foundation, describes this as the “gold standard” for those with established heart disease or high risk.
The management strategy is built upon four distinct pillars of escalation:
- Nutrition: The foundational core of obesity management, focusing on dietary quality and caloric balance.
- Physical Activity: A recommendation of 30 minutes of moderate to vigorous activity, though experts emphasize that any movement is better than none.
- Pharmacological Intervention: The use of GLP-1 medications, such as semaglutide, for long-term weight management and cardiovascular protection.
- Surgical Intervention: Reserved for patients for whom the previous three pillars have proven ineffective.
| Treatment Pillar | Primary Goal | Clinical Application |
|---|---|---|
| Nutrition & Exercise | Foundational Health | First-line for all patients |
| GLP-1 Medications | Weight & CV Risk Reduction | Indicated for high-risk CVD patients |
| Bariatric Surgery | Significant Weight Loss | Final escalation for non-responsive cases |
While GLP-1 drugs were originally developed for diabetes management, researchers found they provided incidental but profound benefits for the heart. Clinical data indicates that individuals with established heart disease who took these medications saw a 20 per cent reduction in future cardiovascular events, while also reporting improved quality of life and symptom relief in specific types of heart failure.
Addressing the Chronic Nature of Obesity
The consensus statement aims to dismantle the long-standing stigma that obesity is a failure of motivation. Professor Jennings noted that the public narrative has historically viewed obesity as an individualized problem of willpower, whereas clinical understanding now recognizes it as a complex, chronic-relapsing condition often beyond the direct control of the individual.
This perspective is echoed by Dr. Mark Mellor, a general practitioner and task force member. Seeing up to 30 patients a day, Mellor argues that failing to treat obesity in a patient with cardiovascular disease is a missed opportunity to improve overall health outcomes. He emphasizes the need for “longitudinal” and “patient-centered” care rather than short-term measures.
The urgency of this shift is highlighted by rising national health data. According to the 2022 National Health Survey, 31.7 per cent of Australian adults are clinically classified as obese, a significant increase from 24.4 per cent in 2007. 34 per cent of adults are classified as overweight, signaling a widespread public health challenge that extends beyond the clinic and into the environment—specifically the availability of ultra-processed, high-salt and high-sugar foods.
The Barrier of Cost and Accessibility
Despite the clinical endorsement, a significant gap remains in patient access. Currently, no TGA-indicated medicines for weight management are listed on the Pharmaceutical Benefit Scheme (PBS), meaning many patients must pay out-of-pocket for these high-cost medications.
Natalie Raffoul, senior manager for healthcare programs and clinical strategy at the Heart Foundation, expressed hope that these medications will become more widely available. The task force is advocating for the government to make these treatments accessible to those who need them most, ideally at a minimal cost to the patient, to ensure that the benefits of the new guidelines are not limited to those with higher socioeconomic status.
Professor Elif Ekinci, director of the Australian Centre for Accelerating Diabetes Innovations, noted that while medications like Mounjaro, Wegovy, and Ozempic are widely available, it is crucial for patients to discuss both the potential benefits and the potential side effects with their clinicians. The guidelines are intended to provide the necessary evidence base for these conversations between families and healthcare providers.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
For those struggling with body image or eating disorders, support is available via the Butterfly National Helpline at 1800 ED HOPE (1800 33 4673).
The medical community now looks toward the Australian government and the Pharmaceutical Benefits Advisory Committee to determine if and when these cardiovascular-protective medications will be subsidized, a move that would drastically expand access to the “gold standard” of care outlined in the consensus statement.
Do you believe medication should be more widely subsidized for heart health? Share your thoughts in the comments or share this article with your network.
